SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2 STUDY

PCSK9 antibodies under development require dosing every (Q) 2 weeks (W) or large monthly doses to maintain sustained LDL-C reductions. LY3015014 (LY) is a humanized monoclonal antibody with an inherently longer duration of action. This phase 2 study assessed the LDL-C lowering effect of LY given